BRIGHT MINDS BIOSCIENCES INC. (DRUG) Financial Statements
BRIGHT MINDS BIOSCIENCES INC. (DRUG) files with the U.S. Securities and Exchange Commission under CIK 0001827401. 10KGenie shows its annual statements from SEC filings.
Key Figures, Fiscal Year 2024
- Net Income
- -2.80 million CAD
- Total Assets
- 6.10 million CAD
- Net Cash from Operations
- -1.85 million CAD
Fiscal year ended Sep 30, 2024. Latest periodic SEC filing: Dec 31, 2024. Source: SEC filings (EDGAR XBRL). Amounts in CAD.
Open the full financial statements for DRUG in 10KGenie
Data from SEC EDGAR filings. 10KGenie is not affiliated with the SEC. SEC Filing History